Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance
Source: SeekingAlpha
2025-05-06 23:14:22 ET
More on Rigel Pharmaceuticals
- Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript
- Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability
- Rigel Looks Interesting, But Let's Wait For A Lower Price
- Rigel Pharmaceuticals Q1 2025 Earnings Preview
- Rigel settles patent litigation regarding its immune thrombocytopenia treatment
Read the full article on Seeking Alpha
For further details see:
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance
Rigel Pharmaceuticals Inc.
NASDAQ: RIGL
RIGL Trading
-2.18% G/L:
$25.844 Last:
155,858 Volume:
$26.27 Open:
RIGL Latest News
March 16, 2026 06:56:37 pm
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
March 03, 2026 04:01:00 pm
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RIGL Stock Data
$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
